Intra-Cellular Therapies, Inc.
ITCI
Rankning i aktier
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aktiekurs
$131.87
Senast synkroniserad: 2025-04-02
Marknadsvärde
$12.68B
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Vinst för Intra-Cellular Therapies, Inc. (ITCI)
Vinst i Dec 2024 TTM: $-74.20M
Enligt de senaste finansiella rapporterna från Intra-Cellular Therapies, Inc. är företagets nuvarande vinst $-74.20M. År 2023 hade företaget en vinst på $-139.04M, en ökning jämfört med vinsten år 2022 som var $-256.25M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Intra-Cellular Therapies, Inc. från 2013 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $-74.20M | 0.00% |
| 2024 | $-74.20M | -46.63% |
| 2023 | $-139.04M | -45.74% |
| 2022 | $-256.25M | -9.81% |
| 2021 | $-284.12M | 25.17% |
| 2020 | $-226.99M | 53.66% |
| 2019 | $-147.72M | -4.77% |
| 2018 | $-155.13M | 56.96% |
| 2017 | $-98.83M | -14.33% |
| 2016 | $-115.36M | 10.09% |
| 2015 | $-104.79M | 241.45% |
| 2014 | $-30.69M | 14.30% |
| 2013 | $-26.85M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -2,478.01% |
IN
|
